Lifecare (LIFE)

[TekBot]

LIFE Improved read out distance for sensor preparing for longevity trials in dogs

Bergen, Norway, June 10th, 2024: Today, Lifecare ASA (LIFE), a clinical stage
medical sensor company developing the next generation Continuous Glucose
Monitor (CGM), announces that the company have improved the read-out distance
…

Vis børsmeldingen

from sensor to the read-out device.

Reference is made to previous communications in the Q1 reporting regarding the
need to improve the read-out distance to start the pending longevity study.
This longevity study on dogs will be performed at the Norwegian University of
Life Sciences (NMBU), located in Ås, close to Oslo.

In the longevity study, the company will introduce wireless communication
between the implanted sensor and the outside read-out device. The Lifecare
team has been working with external specialized consultants to improve the
signal read-out distance to meet requirements, as defined by Lifecare.

The reports from factory acceptance tests conducted by Lifecare confirms
satisfactory read-out distance. This conclusion being important for two
reasons. Firstly, this means that Lifecare now are ready to start the
longevity study in dogs, only pending final internal in-vitro sensor quality
control. Secondly, the confirmed read-out distance meets Lifecare’s
requirements from a product development perspective, additional improvements
for distance read-out are not expected to be necessary going forward. Given
that the quality in-vitro testing goes as planned, the longevity study can
start at NMBU in mid-June.

• Integration of wireless communication in our state-of-the-art sensor is a
  sensitive matter, although solvable. Our engineers and scientist have improved
  the read-out distance. For us, this was a question of when, not if, we could
  meet the defined requirements. Now we can look forward to starting the
  longevity study in June. Furthermore, given good results from the longevity
  study and the ongoing progress towards automated production, the confirmed
  read-out distance is an important progress towards product readiness in the
  veterinary market, says CEO Joacim Holter at Lifecare.

Managing Director, Jo Amundstad of the subsidiary Lifecare Veterinary, will be
responsible for carrying out the study in collaboration with NMBU. - We are
fortunate to have with us some of the leading experts in internal medicine at
NMBU to take part in the studies. Among these, PhD candidate Sivert Nerhagen
has already been employed. He has taken part in the important preparations for
the longevity study, says Amundstad. He points out that the recruitment
process of patients for the study also is well under way.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare’s main focus is
to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
(“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s
sensor technology is referred to as “Sencell” and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 19 no. 3. The information was submitted for publication
at 2024-06-10 08:25 CEST.

Kilde

[TekBot]

Lifecare ASA: Mandatory notification of trade

Reference is made to the stock exchange announcement published by Lifecare ASA
(the “Company”) on 30 May 2024, regarding the commencement of the subscription
period in the partially underwritten rights issue (the “Rights Issue”).
…

Vis børsmeldingen

Member of the Board of Directors in Lifecare ASA and primary insider Tone
Kvåle has today subscribed 40,000 shares in the Rights Issue at a price of NOK
1,52442 per share. Please see the attached PDMR-form for further details.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare’s main focus is
to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
(“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s
sensor technology is referred to as “Sencell” and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2024-06-10 10:45 CEST.

Kilde

[TekBot]

Lifecare ASA: Mandatory notification of trade

Reference is made to the stock exchange announcement published by Lifecare ASA
(the “Company”) on 30 May 2024, regarding the commencement of the subscription
period in the partially underwritten rights issue (the “Rights Issue”).
…

Vis børsmeldingen

Hannibal Invest AS, a company closely associated with Hans Hekland, member of
the board of directors of, and primary insider in, the Company, has today
subscribed 21,888 shares in the Rights Issue at a price of NOK 1.52442 per
share. Please see the attached PDMR-form for further details.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare’s main focus is
to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
(“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s
sensor technology is referred to as “Sencell” and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2024-06-12 10:58 CEST.

Kilde

[TekBot]

Lifecare ASA: Last day of the Subscription Period in the Rights Issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THIS ANNOUNCEMENT.

Reference is made to the previous stock exchange announcements published by
Lifecare ASA (“Lifecare” or the “Company”) regarding the partially
underwritten rights issue of between 49,199,128 and 59,038,955 new shares in
the Company (the “Offer Shares”) at a subscription price of NOK 1.52442 per
Offer Share (the “Subscription Price”), raising gross proceeds between NOK 75
million and NOK 90 million (the “Rights Issue”). The subscribers in the Rights
Issue will be allocated one warrant for every two Offer Shares allocated to,
and paid, by them in the Rights Issue (the “Warrants”). The Company will issue
between 24,599,564 and 29,519,478 Warrants.

The subscription period for the Rights Issue (the “Subscription Period”)
expires today, 13 June 2024, at 16:30 hours (CEST). Over-subscription and
subscription without subscription rights is permitted, however, there can be
no assurance that Offer Shares will be allocated for such subscriptions.

Subscriptions for Offer Shares must be made within the expiry of the
Subscription Period and may either be made through the VPS online subscription
system or by submitting a correctly completed subscription form to Carnegie AS
(acting as the manager for the Rights Issue, the “Manager”), in accordance
with the instructions set out in the Prospectus (as defined below). The
Warrants will automatically be subscribed for through delivery of a correctly
completed subscription prior to the expiry of the Subscription Period.

Subscription rights that are not used to subscribe for Offer Shares before the
expiry of the Subscription Period will have no value and will lapse without
compensation to the holder.

For more information, and the complete terms and conditions of the Rights
Issue, please refer to the prospectus for the Rights Issue dated 28 May 2024
(the “Prospectus”). The Prospectus, including the subscription form for the
Rights Issue, is, subject to applicable local securities laws, available via
the website of the Company (www.lifecare.no/preferential-rights-issue) and at
the website of the Manager
(www.carnegie.no/ongoing-prospectuses-and-offerings/).

For more information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

For information about the Rights Issue, please contact the Manager: +47 22 00
93 60

Disclosure regulation:

This information is published in accordance with the requirements of the
Continuing Obligations for companies listed on Euronext Growth Oslo and
section 5-12 of the Norwegian Securities Trading Act.

About Lifecare:

Lifecare is a clinical stage medical sensor company developing technology for
sensing and monitoring of various body analytes. Lifecare’s main focus is to
bring the next generation of Continuous Glucose Monitoring (“CGM”) systems to
market. Lifecare enables osmotic pressure as sensing principle, combined with
the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR”)
on the sensor body for read-out of pressure variations. Lifecare’s sensor
technology is referred to as “Sencell” and is suitable for identifying and
monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Important information:

Any offering of the securities referred to in this announcement will be made
by means of the Prospectus which has been registered with the Norwegian
Register of Business Enterprises. Neither the Financial Supervisory Authority
of Norway nor any other public authority has carried out any form of review,
control, or approval of the Prospectus. The Prospectus does not constitute an
EEA prospectus.

This announcement is an advertisement and is not a prospectus for the purposes
of Regulation (EU) 2017/1129 of the European Parliament and of the Council of
14 June 2017 on prospectuses to be published when securities are offered to
the public or admitted to trading on a regulated market, and repealing
Directive 2003/71/EC (as amended) as implemented in any EEA Member State (the
“Prospectus Regulation”). Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained
in the Prospectus. Copies of the Prospectus are available from the Company’s
registered office and, subject to certain exceptions, on the website of the
Manager.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer
without an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred
to as “Relevant Persons”). These materials are directed only at Relevant
Persons and must not be acted on or relied on by persons who are not Relevant
Persons. Any investment or investment activity to which this announcement
relates is available only to Relevant Persons and will be engaged in only with
Relevant Persons. Persons distributing this communication must satisfy
themselves that it is lawful to do so.

This document is not for publication or distribution in, directly or
indirectly, Australia, Canada, Japan, the United States or any other
jurisdiction in which such release, publication or distribution would be
unlawful, and it does not constitute an offer or invitation to subscribe for
or purchase any securities in such countries or in any other jurisdiction. In
particular, the document and the information contained herein should not be
distributed or otherwise transmitted into the United States or to publications
with a general circulation in the United States of America.

The Manager is acting for the Company in connection with the Rights Issue and
no one else and will not be responsible to anyone other than the Company for
providing the protections afforded to its clients or for providing advice in
relation to the Rights Issue or any transaction or arrangement referred to in
this announcement.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies and other important
factors which are difficult or impossible to predict and are beyond its
control. Such risks, uncertainties, contingencies and other important factors
could cause actual events to differ materially from the expectations expressed
or implied in this release by such forward-looking statements. The
information, opinions and forward-looking statements contained in this
announcement speak only as at its date and are subject to change without
notice, and each of the Company, the Manager and its affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new
information, future developments or otherwise. This announcement is made by
and is the responsibility of, the Company. Neither the Manager nor any of its
affiliates makes any representation as to the accuracy or completeness of this
announcement and none of them accepts any responsibility for the contents of
this announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied
upon in substitution for the exercise of independent judgment. It is not
intended as investment advice and under no circumstances is it to be used or
considered as an offer to sell, or a solicitation of an offer to buy any
securities or a recommendation to buy or sell any securities of the Company.
No reliance may be placed for any purpose on the information contained in this
announcement or its accuracy, fairness or completeness. Neither the Manager
nor any of its affiliates accepts any liability arising from the use of this
announcement.

Kilde

[TekBot]

LIFE Successful in-vitro quality testing of sensor

Bergen, Norway, June 13th, 2024: Today, Lifecare ASA (LIFE), a clinical stage
medical sensor company developing the next generation Continuous Glucose
Monitor (CGM), announces that the company has concluded a successful in-vitro
…

Vis børsmeldingen

quality test of sensor for use in longevity study.

Reference is made to stock exchange notification June 10th, 2024. The internal
in-vitro quality test has been successfully conducted.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare’s main focus is
to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
(“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s
sensor technology is referred to as “Sencell” and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 19 no. 3. The information was submitted for publication
at 2024-06-13 14:33 CEST.

Kilde

[Rooney1]

Toppers, jeg tror denne fort kan gå 10 * kursen i dag.
les dere opp på denne, milliard marked ligger nå åpent for Lifcare.

[TekBot]

Lifecare ASA: Preliminary results of the Rights Issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THIS ANNOUNCEMENT.

Reference is made to the previous stock exchange announcements published by
Lifecare ASA (“Lifecare” or the “Company”) regarding the partially
underwritten rights issue of between 49,199,128 and 59,038,955 new shares in
the Company (the “Offer Shares”) at a subscription price of NOK 1.52442 per
Offer Share (the “Subscription Price”), raising gross proceeds between NOK 75
million and NOK 90 million (the “Rights Issue”). The subscribers in the Rights
Issue will be allocated one warrant for every two Offer Shares allocated to,
and paid, by them in the Rights Issue (the “Warrants”).

The subscription period for the Rights Issue expired at 16:30 hours (CEST)
today, 13 June 2024.

Preliminary results indicate that the Company has received subscriptions for
83,313,359 Offer Shares in the Rights Issue.

Allocation of the Offer Shares will take place on or about 14 June 2024 in
accordance with the allocation criteria set out in the prospectus for the
Rights Issue dated 28 May 2024 (the “Prospectus”).

The results of the Rights Issue will be published shortly thereafter, and
letters regarding allocation of the Offer Shares and Warrants and the
corresponding subscription amount to be paid by each subscriber, are expected
to be distributed on or about 14 June 2024.

The payment for the Offer Shares allocated to a subscriber falls due on or
about 18 June 2024.

For more information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

For information about the Rights Issue, please contact Carnegie AS (the
“Manager”): +47 22 00 93 60

About Lifecare:
Lifecare is a clinical stage medical sensor company developing technology for
sensing and monitoring of various body analytes. Lifecare’s main focus is to
bring the next generation of Continuous Glucose Monitoring (“CGM”) systems to
market. Lifecare enables osmotic pressure as sensing principle, combined with
the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR”)
on the sensor body for read-out of pressure variations. Lifecare’s sensor
technology is referred to as “Sencell” and is suitable for identifying and
monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Important information:

Any offering of the securities referred to in this announcement will be made
by means of the Prospectus which has been registered with the Norwegian
Register of Business Enterprises. Neither the Financial Supervisory Authority
of Norway nor any other public authority has carried out any form of review,
control, or approval of the Prospectus. The Prospectus does not constitute an
EEA prospectus.

This announcement is an advertisement and is not a prospectus for the purposes
of Regulation (EU) 2017/1129 of the European Parliament and of the Council of
14 June 2017 on prospectuses to be published when securities are offered to
the public or admitted to trading on a regulated market, and repealing
Directive 2003/71/EC (as amended) as implemented in any EEA Member State (the
“Prospectus Regulation”). Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained
in the Prospectus. Copies of the Prospectus are available from the Company’s
registered office and, subject to certain exceptions, on the website of the
Manager.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer
without an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred
to as “Relevant Persons”). These materials are directed only at Relevant
Persons and must not be acted on or relied on by persons who are not Relevant
Persons. Any investment or investment activity to which this announcement
relates is available only to Relevant Persons and will be engaged in only with
Relevant Persons. Persons distributing this communication must satisfy
themselves that it is lawful to do so.

This document is not for publication or distribution in, directly or
indirectly, Australia, Canada, Japan, the United States or any other
jurisdiction in which such release, publication or distribution would be
unlawful, and it does not constitute an offer or invitation to subscribe for
or purchase any securities in such countries or in any other jurisdiction. In
particular, the document and the information contained herein should not be
distributed or otherwise transmitted into the United States or to publications
with a general circulation in the United States of America.

The Manager is acting for the Company in connection with the Rights Issue and
no one else and will not be responsible to anyone other than the Company for
providing the protections afforded to its clients or for providing advice in
relation to the Rights Issue or any transaction or arrangement referred to in
this announcement.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies and other important
factors which are difficult or impossible to predict and are beyond its
control. Such risks, uncertainties, contingencies and other important factors
could cause actual events to differ materially from the expectations expressed
or implied in this release by such forward-looking statements. The
information, opinions and forward-looking statements contained in this
announcement speak only as at its date and are subject to change without
notice, and each of the Company, the Manager and its affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new
information, future developments or otherwise. This announcement is made by
and is the responsibility of, the Company. Neither the Manager nor any of its
affiliates makes any representation as to the accuracy or completeness of this
announcement and none of them accepts any responsibility for the contents of
this announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied
upon in substitution for the exercise of independent judgment. It is not
intended as investment advice and under no circumstances is it to be used or
considered as an offer to sell, or a solicitation of an offer to buy any
securities or a recommendation to buy or sell any securities of the Company.
No reliance may be placed for any purpose on the information contained in this
announcement or its accuracy, fairness or completeness. Neither the Manager
nor any of its affiliates accepts any liability arising from the use of this
announcement.

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 19 no. 3. The information was submitted for publication
at 2024-06-13 19:21 CEST.

Kilde

[torsteinius]

@Rooney1

Toppers, jeg tror denne fort kan gå 10 * kursen i dag.
les dere opp på denne, milliard marked ligger nå åpent for Lifcare.

Enig, les og lær;

Stort diabetes-gjennombrudd: Pasient ble helt frisk

Det tar sikker en del tid før dette blir tilgjengelig for hvermannsen, men pumpe og dumpe- samt pumpe og kjøre emisjon-opplegget til Life holder jeg meg unna.

[TekBot]

Lifecare ASA: Final results of the Rights Issue and resolution to increase the share capital for settlement of the underwriting commission

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THIS ANNOUNCEMENT.

Reference is made to the previous stock exchange announcements published by
Lifecare ASA (“Lifecare” or the “Company”) regarding the partially
underwritten rights issue of between 49,199,128 and 59,038,955 new shares in
the Company (the “Offer Shares”) at a subscription price of NOK 1.52442 per
Offer Share (the “Subscription Price”), raising gross proceeds between NOK 75
million and NOK 90 million (the “Rights Issue”). The subscribers in the Rights
Issue will be allocated one warrant for every two Offer Shares allocated to,
and paid, by them in the Rights Issue (the “Warrants”). The subscription
period for the Rights Issue (the “Subscription Period”) expired at 16:30 hours
(CEST) yesterday, 13 June 2024.

At the expiry of the Subscription Period, the Company had received valid
subscriptions for a total of 83,313,359 Offer Shares.

Allocation of the Offer Shares and Warrants has been completed in accordance
with the allocation criteria set out in the prospectus for the Rights Issue
dated 28 May 2024 (the “Prospectus”). The board of directors of the Company
(the “Board of Directors”) has allocated a total of 59,038,955 Offer Shares.
Based on the number of Offer Shares allocated, the Company has allocated
29,519,478 Warrants, subject to payment of the relevant Offer Shares.

As the Rights Issue attracted subscriptions above the underwritten amounts, no
allocations have been made based on the underwriting commitments for the
Rights Issue.

The subscriptions received will, subject to payment, provide the Company with
approximately NOK 90 million in gross proceeds.

Subject to the Warrants and the Additional Warrants (as defined below) being
exercised at the maximum subscription price of NOK 1.98174 (the subscription
price in the Rights Issue plus 30%), the Company may in total receive proceeds
of up to approximately NOK 108 million.

Notifications of allocated Offer Shares and Warrants and the corresponding
subscription amount to be paid by each subscriber are expected to be
distributed today, 14 June 2024. The payment for the Offer Shares allocated to
a subscriber falls due on 18 June 2024 in accordance with the payment
procedures described in the Prospectus. The Warrants are allocated free of
charge.

The Offer Shares are expected to be tradable on Euronext Growth Oslo from and
including 20 June 2024. The Company will use reasonable efforts to seek to
ensure that the Warrants are admitted to trading on a relevant trading venue
as soon as possible following completion of the Rights Issue but there can be
no assurance that such admittance to trading will be obtained.

Pursuant to the underwriting agreements for the Rights Issue dated 25 April
2024, each underwriter is entitled to an underwriting fee as compensation for
their respective underwriting obligation.

Munkekullen 5 Förvaltning AB and Buntel AB, having underwritten a total of NOK
50 million of the Rights Issue (the “Top Guarantee”), are entitled to
compensation of an aggregate of 25,000,000 warrants at equal terms to the
Warrants issued in the Rights Issue (the “Additional Warrants”) that will be
issued in accordance with the resolution made by the extraordinary general
meeting of the Company held on 16 May 2024.

Teigland Eiendom AS, Lacal AS, Tjelta AS, and Hannibal Invest AS, having
underwritten a total of NOK 25 million of the Rights Issue (the “Bottom
Guarantee”), are entitled to compensation of 10% of their underwritten amount
under the Bottom Guarantee, which they may elect to receive in cash or in kind
(or in a combination thereof) through receiving new shares in the Company at
the subscription price in the Rights Issue. If such new shares are issued, a
separate stock exchange notice will be published regarding this.

The Offer Shares may not be transferred or traded before they have been fully
paid and the share capital increases pertaining to the Offer Shares has been
registered with the Norwegian Register of Business Enterprises (Nw.
Foretaksregisteret). Neither the Warrants nor the Additional Warrants may be
transferred or traded before they have been registered in the Norwegian
Register of Business Enterprises (Nw. Foretaksregisteret). It is expected that
the share capital increase pertaining to the Offer Shares, as well as the
issuance of the Warrants, will be registered in the Norwegian Register of
Business Enterprises on or about 20 June 2024, and that the Offer Shares and
the Warrants will be delivered to the VPS accounts of the subscribers to whom
they are allocated on or about the next day.

For more information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

For information about the Rights Issue, please contact Carnegie AS (the
“Manager”): +47 22 00 93 60

About Lifecare:

Lifecare is a clinical stage medical sensor company developing technology for
sensing and monitoring of various body analytes. Lifecare’s main focus is to
bring the next generation of Continuous Glucose Monitoring (“CGM”) systems to
market. Lifecare enables osmotic pressure as sensing principle, combined with
the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR”)
on the sensor body for read-out of pressure variations. Lifecare’s sensor
technology is referred to as “Sencell” and is suitable for identifying and
monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Important information:

Any offering of the securities referred to in this announcement will be made
by means of the Prospectus which has been registered with the Norwegian
Register of Business Enterprises. Neither the Financial Supervisory Authority
of Norway nor any other public authority has carried out any form of review,
control, or approval of the Prospectus. The Prospectus does not constitute an
EEA prospectus.

This announcement is an advertisement and is not a prospectus for the purposes
of Regulation (EU) 2017/1129 of the European Parliament and of the Council of
14 June 2017 on prospectuses to be published when securities are offered to
the public or admitted to trading on a regulated market, and repealing
Directive 2003/71/EC (as amended) as implemented in any EEA Member State (the
“Prospectus Regulation”). Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained
in the Prospectus. Copies of the Prospectus are available from the Company’s
registered office and, subject to certain exceptions, on the website of the
Manager.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer
without an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred
to as “Relevant Persons”). These materials are directed only at Relevant
Persons and must not be acted on or relied on by persons who are not Relevant
Persons. Any investment or investment activity to which this announcement
relates is available only to Relevant Persons and will be engaged in only with
Relevant Persons. Persons distributing this communication must satisfy
themselves that it is lawful to do so.

This document is not for publication or distribution in, directly or
indirectly, Australia, Canada, Japan, the United States or any other
jurisdiction in which such release, publication or distribution would be
unlawful, and it does not constitute an offer or invitation to subscribe for
or purchase any securities in such countries or in any other jurisdiction. In
particular, the document and the information contained herein should not be
distributed or otherwise transmitted into the United States or to publications
with a general circulation in the United States of America.

The Manager is acting for the Company in connection with the Rights Issue and
no one else and will not be responsible to anyone other than the Company for
providing the protections afforded to its clients or for providing advice in
relation to the Rights Issue or any transaction or arrangement referred to in
this announcement.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies and other important
factors which are difficult or impossible to predict and are beyond its
control. Such risks, uncertainties, contingencies and other important factors
could cause actual events to differ materially from the expectations expressed
or implied in this release by such forward-looking statements. The
information, opinions and forward-looking statements contained in this
announcement speak only as at its date and are subject to change without
notice, and each of the Company, the Manager and its affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new
information, future developments or otherwise. This announcement is made by
and is the responsibility of, the Company. Neither the Manager nor any of its
affiliates makes any representation as to the accuracy or completeness of this
announcement and none of them accepts any responsibility for the contents of
this announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied
upon in substitution for the exercise of independent judgment. It is not
intended as investment advice and under no circumstances is it to be used or
considered as an offer to sell, or a solicitation of an offer to buy any
securities or a recommendation to buy or sell any securities of the Company.
No reliance may be placed for any purpose on the information contained in this
announcement or its accuracy, fairness or completeness. Neither the Manager
nor any of its affiliates accepts any liability arising from the use of this
announcement.

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2024-06-14 12:11 CEST.

Kilde

[TekBot]

LIFE: Satisfied with the final results of the Rights Issue

Bergen, Norway, 14 June, 2024: Today, Lifecare ASA (LIFE), a clinical stage
medical sensor company developing the next generation Continuous Glucose
Monitor (CGM), announces that all valid subscriptions from investors with
…

Vis børsmeldingen

subscription rights have been allocated in accordance with the allocation
criteria set out in the prospectus for the Rights Issue.

Reference is made to the previous stock exchange announcements published by
Lifecare ASA (“Lifecare” or the “Company”) regarding Final results of the
Rights Issue today 14 June.

• We are grateful for the trust shown by both existing and new shareholders in
  the completion of the Rights Issue. We have observed a high level of demand
  during the subscription period, resulting in an over-subscription of 40%. All
  investors with subscriptions rights have been allocated their subscription and
  over-subscription has been allocated according to the allocation criteria set
  out in the prospectus, says CEO Joacim Holter at Lifecare.

• We are satisfied with the final result, as it provides the company with a
  strengthened financial foundation. The Rights Issue has also been a crucial
  step towards the uplisting on the Oslo Stock Exchange’s main list, ensuring
  compliance with the financial requirements for the uplisting. The next step
  for Lifecare, is the longevity study on dogs, which will be in collaboration
  with the Norwegian University of Life Sciences (NMBU), says Holter.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare’s main focus is
to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
(“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s
sensor technology is referred to as “Sencell” and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

Kilde

[stAMy]

Spiller ingen rolle når selskapet ledes av kjeltringer.

[Cruiser]

Er det noen som kan fortelle hvorfor Joacim Holter &Co anses som kjeltringer. Skulle gjerne ha visst det før det tas en beslutning om man bør ta ett lodd eller la være.

[TekBot]

Lifecare ASA: Mandatory notification of trade

Reference is made to the stock exchange announcement published by Lifecare ASA
(the “Company”) on 30 May 2024, regarding the commencement of the subscription
period in the partially underwritten rights issue (the “Rights Issue”).
…

Vis børsmeldingen

Hannibal Invest AS, a company closely associated with Hans Hekland, board
member of the Company, has today subscribed 12.809 shares in the Rights Issue
at a price of NOK 1,52442 per subscription right. Please see the attached
PDMR-form for further details.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare’s main focus is
to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
(“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s
sensor technology is referred to as “Sencell” and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2024-06-14 16:31 CEST.

Kilde

[rockpus]

Du finner mye om dette på Xtrainvestor sitt forum.
Der er også en anonym deltaker som de fleste påstår er avslørt som Holter.

[TekBot]

LIFE Longevity trials in dogs starts today

Bergen, Norway, 18 June 2024: Today, Lifecare ASA (LIFE), a clinical stage
medical sensor company developing the next generation Continuous Glucose
Monitor (CGM), announces that the company will starts the longevity trials in
…

Vis børsmeldingen

dogs today.

Reference is made to stock exchange notification June 10th and June 13th,
2024. The company have improved the read-out distance from sensor to the
read-out device and the internal in-vitro quality test has been successfully
conducted.

The longevity study on dogs will be performed at the Norwegian University of
Life Sciences (NMBU), located in Ås, close to Oslo. Managing Director, Jo
Amundstad of the subsidiary Lifecare Veterinary, will be responsible for
carrying out the study in collaboration with NMBU.

– We have carried out the necessary preparations and procedures of the
longevity study. The team consists of some of the leading experts in internal
medicine at NMBU and their important contribution towards the study we are
starting now is highly valued. Recruitment of patients has worked out as
planned and the first dog is ready for implementation of the wireless sensor
today, says Jo Amunstad.

Last week Lifecare Laboratory in Mainz conducted the in-vitro quality test of
the wireless communication between the sensor and a read-out device. In their
report they have concluded that the read-out signals from the sensor in the
in-vitro testing environment meets necessary requirements from a product
development perspective. Hence the company are ready to start the longevity
study in dogs in today.

• The results and learnings from the longevity study and the ongoing progress
  towards automated production are important steps towards product readiness in
  the veterinary market, says CEO Joacim Holter at Lifecare.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare’s main focus is
to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
(“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s
sensor technology is referred to as “Sencell” and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

Kilde

[TekBot]

Lifecare ASA: Share capital increase and warrants registered

Reference is made to the stock exchange announcement published by Lifecare ASA
(“Lifecare” or the “Company”) on 14 June 2024 regarding the final results of
the partially underwritten rights issue of new shares in the Company (the
…

Vis børsmeldingen

“Rights Issue”).

The share capital increase pertaining to the issuance of 59,038,955 new shares
in the Rights Issue has now been registered with the Norwegian Register of
Business Enterprises. The Company’s new share capital is NOK 77,561,878.80
divided on 193,904,697 shares, each with a par value of NOK 0.40.

The subscribers in the Rights Issue were allocated one warrant for every two
shares allocated to, and paid by, them in the Rights Issue (the “Warrants”).
Further, Munkekullen 5 Förvaltning AB and Buntel AB, having underwritten a
total of NOK 50 million of the Rights Issue, were allocated a total of
25,000,000 warrants at equal terms to the Warrants, as compensation for their
underwriting commitment (the “Additional Warrants”). The issuance of in total
29,519,478 Warrants and 25,000,000 Additional Warrants has now been registered
with the Norwegian Register of Business Enterprises.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare’s main focus is
to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
(“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s
sensor technology is referred to as “Sencell” and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2024-06-25 14:47 CEST.

Kilde

[TekBot]

Lifecare ASA: Information about the warrants issued in connection with the Rights Issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THIS ANNOUNCEMENT.

Reference is made to the stock exchange announcement published by Lifecare ASA
(the “Company”) on 25 June 2024, regarding the registration of new share
capital following completion of the rights issue raising gross proceeds of
approximately NOK 90 million (the “Rights Issue”) and the registration of
warrants allocated in connection with the Rights Issue.

The subscribers in the Rights Issue were allocated one warrant for every two
offer shares allocated to and paid by them in the Rights Issue. In total,
29,519,478 warrants were allocated to the subscribers in the Rights Issue.
Further, Munkekullen 5 Förvaltning AB and Buntel AB, having underwritten a
total of NOK 50 million of the Rights Issue, were allocated a total of
25,000,000 warrants at equal terms to the warrants allocated to subscribers in
the Rights Issue, as compensation for their underwriting commitment.
Consequently, a total of 54,519,478 warrants (the “Warrants”) were allocated
to subscribers in the Rights Issue, Munkekullen 5 Förvaltning AB and Buntel
AB.

The Warrants may be exercised during the exercise period from 2 June 2025 to
13 June 2025 (the “Exercise Period”).

The Warrants will be listed and tradable on Euronext Growth Oslo under the
ticker code “LIFES”. The trading in the Warrants will be halted four days
before the end of the Exercise Period to facilitate settlement of exercised
Warrants. The Warrants will be tradable from 27 June 2024 to 16:30 (CEST) on 6
June 2025. The Warrants will hence only be tradable during parts of the
Exercise Period.

If all the Warrants are exercised, the Company expects to raise additional
gross proceeds of up to approximately NOK 108 million (based on the maximum
exercise price of NOK 1.98174). In the event that Warrants are not exercised,
the gross proceeds will be reduced corresponding to the proportion of Warrants
that are not exercised.

Each Warrant will give the holder a right to subscribe for one new share in
the Company at an exercise price per share equal to the volume-weighted
average price (VWAP) of the company’s shares on Euronext Growth Oslo on the
three last trading days prior to the first date on which the holder can
exercise the Warrant in the exercise period less 30%, but in any event (i) not
lower than the par value of the Company’s shares (NOK 0.40) and (ii) not
exceeding the subscription price in the Rights Issue plus 30% (i.e. NOK
1.98174).

Exercise of Warrants is carried out by written notification to the Company,
which must be received by the Company before the expiry of the Exercise
Period. The notice shall include the number of Warrants the holder has and how
many of these are exercised.

Holders of Warrants may either sell the Warrants or use them to subscribe for
shares in the Company within the Exercise Period. As such, the Warrants may
have an economic value for the holders, depending on the prevailing market
price for the shares in the Company. Holders of Warrants who do not sell or
use the Warrants to subscribe for shares in the Company may experience a
dilution of their shareholding in the Company.

If the Warrants are not sold within 16:30 (CEST) on 6 June 2025 or exercised
within 16:30 (CEST) on 13 June 2025 the Warrants will lapse with no
compensation to the holders.

For more information pertaining to the Warrants, please see the national
prospectus prepared for the Rights Issue, dated 28 May 2024 (the
“Prospectus”).

The Prospectus is, subject to applicable local securities laws, available via
the website of the Company (www.lifecare.no/preferential-rights-issue) and at
the website of the Manager (as defined below)
(www.carnegie.no/ongoing-prospectuses-and-offerings).

Contacts:

For more information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

For information about the Rights Issue, please contact Carnegie AS (the
“Manager”): +47 22 00 93 60

About Lifecare:

Lifecare is a clinical stage medical sensor company developing technology for
sensing and monitoring of various body analytes. Lifecare’s main focus is to
bring the next generation of Continuous Glucose Monitoring (“CGM”) systems to
market. Lifecare enables osmotic pressure as sensing principle, combined with
the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR”)
on the sensor body for read-out of pressure variations. Lifecare’s sensor
technology is referred to as “Sencell” and is suitable for identifying and
monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Important information:

The offering of the securities referred to in this announcement was made by
means of the Prospectus which has been registered with the Norwegian Register
of Business Enterprises. Neither the Financial Supervisory Authority of Norway
nor any other public authority has carried out any form of review, control, or
approval of the Prospectus. The Prospectus does not constitute an EEA
prospectus.

This announcement is an advertisement and is not a prospectus for the purposes
of Regulation (EU) 2017/1129 of the European Parliament and of the Council of
14 June 2017 on prospectuses to be published when securities are offered to
the public or admitted to trading on a regulated market, and repealing
Directive 2003/71/EC (as amended) as implemented in any EEA Member State (the
“Prospectus Regulation”). Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained
in the Prospectus. Copies of the Prospectus are available from the Company’s
registered office and, subject to certain exceptions, on the website of the
Manager.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer
without an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred
to as “Relevant Persons”). These materials are directed only at Relevant
Persons and must not be acted on or relied on by persons who are not Relevant
Persons. Any investment or investment activity to which this announcement
relates is available only to Relevant Persons and will be engaged in only with
Relevant Persons. Persons distributing this communication must satisfy
themselves that it is lawful to do so.

This document is not for publication or distribution in, directly or
indirectly, Australia, Canada, Japan, the United States or any other
jurisdiction in which such release, publication or distribution would be
unlawful, and it does not constitute an offer or invitation to subscribe for
or purchase any securities in such countries or in any other jurisdiction. In
particular, the document and the information contained herein should not be
distributed or otherwise transmitted into the United States or to publications
with a general circulation in the United States of America.

The Manager is acting for the Company in connection with the Rights Issue and
no one else and will not be responsible to anyone other than the Company for
providing the protections afforded to its clients or for providing advice in
relation to the Rights Issue or any transaction or arrangement referred to in
this announcement.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies and other important
factors which are difficult or impossible to predict and are beyond its
control. Such risks, uncertainties, contingencies and other important factors
could cause actual events to differ materially from the expectations expressed
or implied in this release by such forward-looking statements. The
information, opinions and forward-looking statements contained in this
announcement speak only as at its date and are subject to change without
notice, and each of the Company, the Manager and its affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new
information, future developments or otherwise. This announcement is made by
and is the responsibility of, the Company. Neither the Manager nor any of its
affiliates makes any representation as to the accuracy or completeness of this
announcement and none of them accepts any responsibility for the contents of
this announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied
upon in substitution for the exercise of independent judgment. It is not
intended as investment advice and under no circumstances is it to be used or
considered as an offer to sell, or a solicitation of an offer to buy any
securities or a recommendation to buy or sell any securities of the Company.
No reliance may be placed for any purpose on the information contained in this
announcement or its accuracy, fairness or completeness. Neither the Manager
nor any of its affiliates accepts any liability arising from the use of this
announcement.

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2024-06-27 07:00 CEST.

Kilde

[TekBot]

LIFE: Successfully completed first week of longevity trials

Bergen, Norway, 27 June 2024: Today, Lifecare ASA (LIFE), a clinical stage
medical sensor company developing the next generation Continuous Glucose
Monitor (CGM), can announce positive results from the first week of sensor
…

Vis børsmeldingen

longevity trials.

Reference is made to press release 18 June 2024 when the company initiated the
trials with wireless readout. Already after the first week of the longevity
trials, conducted at the Norwegian University of Life Sciences (NMBU), the
reports show very positive results. The dog, Elli, is the first patient with
the wireless glucose sensor. During the first seven days, the sensor implanted
under Elli’s skin have transmitted far more than 1000 data points to an
external reader.

• A week’s lifespan under the skin of a dog, in addition to the fact that such
  a large amount of data is read from the implanted sensor, is obviously a huge
  step for us in the right direction, says Managing Director Jo Amundstad of the
  subsidiary Lifecare Veterinary. He is responsible for the study in
  collaboration with NMBU.

• This is really a huge performance. We have been eager to start the longevity
  studies with wireless data-readout, being essential to confirm long-term
  sensor functionality in live tissue. Previously, the Sencell sensor has been
  implanted in clinical trials for up to three days in humans, with wired
  readout. It is groundbreaking for our technology when we note a functionality
  of more than a week in-vivo, and we are very proud of this achievement. The
  study is in its initial phase and this early result encourage us to expect a
  positive news flow from Jo and his team at NMBU as we proceed towards the
  veterinary market, says CEO Joacim Holter at Lifecare.

Elli is in good condition, and she has no complications after implementing the
sensor. Hence the Lifecare-team at NMBU are stepping into the next phase of
the longevity study. – We have placed a Freestyle Libre glucose monitor from
Abbot on Elli’s skin. This will give us a reference source to our Sencell
sensor under the dog’s skin and validate our monitored data. In addition, we
will now prepare to enroll additional veterinary patients to expand the study
in line with our protocol. We are really looking forward to the upcoming
results of the longevity trials, says Jo Amundstad.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare’s main focus is
to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
(“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s
sensor technology is referred to as “Sencell” and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

Kilde

[TekBot]

LIFE: Cleanroom arrived in Hamburg

Bergen, Norway, July 2, 2024: Lifecare ASA (LIFE), a clinical stage medical
sensor company developing the next generation Continuous Glucose Monitor
(CGM), announces that the cleanroom for automated production has arrived in
…

Vis børsmeldingen

Hamburg.

Reference is made to Lifecare’s stock exchange announcement March 5, 2024,
regarding placing a purchase order for cleanroom in connection with the
company’s automated production. Due to disturbances to the sea trade routes
through the middle east and Africa, the shipment of the cleanroom has been
delayed. The shipment is now confirmed as arrived in Hamburg, Germany and is
pending custom clearance.

• Lifecare is subsequently left with no other choice than rescheduling the
  installation of cleanroom to late July and early August, and is aiming to
  launch the Pilot Production Site within the new timeframe of Q3 2024, says CEO
  Joacim Holter at Lifecare.

The importance of cleanroom
Cleanrooms are always required where the airborne particles are likely to
contaminate the final product. Lifecare’s cleanroom, which holds an ISO 7
standard, will ensure that the airborne particles are maintained at a very low
concentration to not interfere with crucial functions of sensor components
during sensor manufacturing. The sensor components consist of micro and nano
technologies sensitive to particles. The airborne particles could potentially
impact the functionality of the sensor by blocking the nano filtration layers
and subsequent flow of the substances in and out of sensor cavities.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare’s main focus is
to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
(“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s
sensor technology is referred to as “Sencell” and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

Kilde

[TekBot]

Lifecare ASA: Mandatory notification of trade

Reference is made to the previous stock exchange announcements published by
Lifecare ASA (the “Company”) regarding the completion of the Rights Issue.

…

Vis børsmeldingen

Hannibal Invest AS, a company closely associated with Hans Hekland, board
member of the Company, has 27 June 2024 subscribed 65,599 shares at a price of
NOK 1,52442 per share, as compensation for the underwriting commitment made in
connection with the Rights Issue. Please see the attached PDMR-form for
further details.

About us

Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare’s main focus is
to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
(“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s
sensor technology is referred to as “Sencell” and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2024-07-02 17:25 CEST.

Kilde